Literature DB >> 15694668

Decreased relative expression level of trefoil factor 3 mRNA to galectin-3 mRNA distinguishes thyroid follicular carcinoma from adenoma.

Toru Takano1, Akira Miyauchi, Hiroshi Yoshida, Kanji Kuma, Nobuyuki Amino.   

Abstract

The expression level of trefoil factor 3 (TFF3) mRNA is a marker for distinguishing thyroid follicular adenomas from carcinomas. However, when measuring the expression level of TFF3 mRNA in fine needle aspiration biopsies, an appropriate internal control mRNA, of which expression is restricted in thyroid epithelial--derived cells, is necessary, since they are often contaminated with a considerable number of blood cells, which do not express TFF3 mRNA. In this study, we evaluated the efficiency of molecular-based diagnosis of thyroid follicular carcinoma by measuring the relative expression of TFF3 mRNA by real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) using galectin-3 mRNA as an internal control. The TFF3/galectin-3 mRNA ratio (T/G ratio) was measured in 54 follicular adenomas and 29 follicular carcinomas. It was markedly decreased in 7 follicular carcinomas of widely invasive type and with evident distant metastases. When the cutoff point was set at 16.0 by a receiver operator characteristic curve, the TG ratio showed good agreement with the pathological diagnosis [kappa=0.55; 95% confidence interval (CI), 0.34-0.77]. This agreement was better when the pathologically questionable cases were excluded (kappa=0.72; 95% CI, 0.49-0.95). Quantification of the T/G ratio may be a useful tool for the distinction between follicular adenomas and carcinomas, which is the most difficult in thyroid pathology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15694668     DOI: 10.1016/j.canlet.2004.07.004

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

Review 1.  How to define follicular thyroid carcinoma?

Authors:  Kurt Werner Schmid; Nadir Rashad Farid
Journal:  Virchows Arch       Date:  2006-02-28       Impact factor: 4.064

2.  Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions.

Authors:  Carrie C Lubitz; Stacy K Ugras; J Jacob Kazam; Biaxin Zhu; Theresa Scognamiglio; Yao-Tseng Chen; Thomas J Fahey
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 3.  Diagnostic utility of galectin-3 in thyroid cancer.

Authors:  Connie G Chiu; Scott S Strugnell; Obi L Griffith; Steven J M Jones; Allen M Gown; Blair Walker; Ivan R Nabi; Sam M Wiseman
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

4.  Validity of multiplex biomarker model of 6 genes for the differential diagnosis of thyroid nodules.

Authors:  Kristine Ducena; Arturs Abols; Janis Vilmanis; Zenons Narbuts; Juris Tārs; Diana Andrējeva; Aija Linē; Valdis Pīrāgs
Journal:  Thyroid Res       Date:  2011-06-27

5.  ADM3, TFF3 and LGALS3 are discriminative molecular markers in fine-needle aspiration biopsies of benign and malignant thyroid tumours.

Authors:  S Karger; K Krause; M Gutknecht; K Schierle; D Graf; F Steinert; H Dralle; D Führer
Journal:  Br J Cancer       Date:  2012-01-05       Impact factor: 7.640

6.  Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers.

Authors:  Seong-Keun Yoo; Seungbok Lee; Su-Jin Kim; Hyeon-Gun Jee; Byoung-Ae Kim; Hyesun Cho; Young Shin Song; Sun Wook Cho; Jae-Kyung Won; Jong-Yeon Shin; Do Joon Park; Jong-Il Kim; Kyu Eun Lee; Young Joo Park; Jeong-Sun Seo
Journal:  PLoS Genet       Date:  2016-08-05       Impact factor: 5.917

7.  Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions.

Authors:  Dalia A Elsers; Mahmoud R A Hussein; Mohammed Hassan Osman; Ghada A Mohamed; Ghada Hosny
Journal:  Asian Pac J Cancer Prev       Date:  2021-10-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.